Brought to you by 
Mesoblast gets $A13.44mm via private financing
08 Jan 2008
Executive Summary
Mesoblast (stem cell therapies for orthopedic conditions) raised $A13.44mm ($11.8mm) through the private placement of 10.5mm shares priced at $A1.28 each (a 5% discount) to Australian institutional and sophisticated investors. The company will use the funds to begin Phase II trials of allogeneic adult stem cells for use in the repair and regeneration of bone and cartilage.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mesoblast gets $A13.44mm via private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice